Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A.

J Clin Invest. 2010 Dec 1;120(12):4569-82. doi: 10.1172/JCI42869.

2.

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.

Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A.

Blood. 2009 Apr 9;113(15):3397-405. doi: 10.1182/blood-2008-07-168773.

3.

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

Parekh S, Privé G, Melnick A.

Leuk Lymphoma. 2008 May;49(5):874-82. doi: 10.1080/10428190801895345. Review.

4.

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.

Dupont T, Yang SN, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L.

Oncotarget. 2016 Jan 19;7(3):3520-32. doi: 10.18632/oncotarget.6513.

5.

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.

Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, Johannet P, Wei Y, Zain J, O'Connor OA.

Blood. 2013 Sep 19;122(12):2104-13. doi: 10.1182/blood-2013-02-485441.

6.

Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.

Cancer Res. 2008 May 1;68(9):3361-9. doi: 10.1158/0008-5472.CAN-07-5817.

7.

FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.

Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, Chapuy B, Shipp M, Chiarle R, Pagano M.

Nature. 2012 Jan 5;481(7379):90-3. doi: 10.1038/nature10688.

8.

Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12.

9.

BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.

Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A.

Blood. 2007 Sep 15;110(6):2067-74.

10.

Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R.

Nature. 2011 Mar 10;471(7337):189-95. doi: 10.1038/nature09730.

11.

A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.

Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH, Yang SN, Garcia M, Coop A, Mackerell AD Jr, Privé GG, Melnick A.

Cancer Cell. 2010 Apr 13;17(4):400-11. doi: 10.1016/j.ccr.2009.12.050.

12.

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.

Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, Jiménez R, Martínez-Climent JA, Criado FJ, Cenador MB, Zhao S, Natkunam Y, Lossos IS, Majeti R, Melnick A, Cobaleda C, Alizadeh AA, Sánchez-García I.

Nat Commun. 2014 Jun 2;5:3904. doi: 10.1038/ncomms4904.

13.

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A.

J Clin Invest. 2015 Nov 3;125(12):4559-71. doi: 10.1172/JCI80714.

14.

PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.

Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S.

Clin Cancer Res. 2014 Sep 15;20(18):4849-60. doi: 10.1158/1078-0432.CCR-14-0034.

15.

BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, Melnick A, Shipp MA.

Blood. 2009 Dec 17;114(26):5315-21. doi: 10.1182/blood-2009-02-204362.

16.

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, Ye K, Farinha P, Horsman DE, Gascoyne RD, Elemento O, Melnick A.

Blood. 2009 May 28;113(22):5536-48. doi: 10.1182/blood-2008-12-193037.

17.

Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.

Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP.

Immunology. 2013 Oct;140(2):259-72. doi: 10.1111/imm.12136.

18.

A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.

Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM, Kormaksson M, MacKerell AD Jr, Xue F, Mason CE, Hiebert SW, Prive GG, Cerchietti L, Bardwell VJ, Elemento O, Melnick A.

Cell Rep. 2013 Aug 15;4(3):578-88. doi: 10.1016/j.celrep.2013.06.016.

19.

Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.

Pera B, Tang T, Marullo R, Yang SN, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J, Cerchietti L, Martin P.

Clin Epigenetics. 2016 Jul 22;8:79. doi: 10.1186/s13148-016-0245-y.

20.

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.

Kalac M, Scotto L, Marchi E, Amengual J, Seshan VE, Bhagat G, Ulahannan N, Leshchenko VV, Temkin AM, Parekh S, Tycko B, O'Connor OA.

Blood. 2011 Nov 17;118(20):5506-16. doi: 10.1182/blood-2011-02-336891.

Items per page

Supplemental Content

Support Center